Stock Notes

Mankind Pharma

Every Finvezto stock note on Mankind Pharma, dated and newest first. Coverage spans pharma.

1 note and counting
21 May 2026
Mankind Pharma guides for double-digit top-line growth and EBITDA margins of 25.5% to 26.5% in FY27.
The margin band is among the strongest in mid-cap pharma, reflecting Mankind's acute therapy dominance and low-cost domestic manufacturing base.

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630. Stock notes are market commentary for general information and education. They are not investment advice, not a recommendation to buy or sell, and do not account for any individual's financial situation. Investment in securities is subject to market risks. Please read all related documents carefully before investing. Past performance is not a guarantee of future results.